Emily I. Leonard

• A development-stage gene therapy company in negotiating multiple cell line in-license agreements.
• Syros in a target discovery, research collaboration and option agreement with Incyte Corporation utilizing the Syros proprietary gene control platform to identify novel therapeutic targets with a focus in myeloproliferative neoplasms (MPNs); $10 million upfront, up to $54 million in target selection and option exercise fees, up to $115 million in milestones, plus potential royalties.
• Gritstone bio, Inc. on a range of funding arrangements, including a BARDA contract for up to $433 million in funding to conduct clinical investigations of a next generation COVID vaccine and a CEPI funding agreement to advance development of a self-amplifying mRNA vaccine candidate against COVID-19 variants.
• Janssen Pharmaceuticals, Inc. in the acquisition from GSK of an NS5a replication complex inhibitor for the treatment of chronic hepatitis C.
• Astellas Pharma Inc. in a global agreement with Medivation to develop and commercialize Xtandi; up-front cash payment of $110 million, up to $335 million upon the attainment of development and regulatory milestones plus up to an additional $320 million in potential commercial milestone payments.
• A multinational pharmaceutical company in an exclusive US commercial arrangement for a subcutaneous migraine therapy administered exclusive through a proprietary needle-free delivery system.
• Natrogen Therapeutics International in agreements granting Takeda Pharmaceutical Company Limited an exclusive license to develop Natrogen’s leading compound and an option to acquire Natrogen.
• Eli Lilly in its agreement to terminate its alliance with Amylin Pharmaceuticals for Byetta and Bydureon and to resolve the outstanding litigation between the companies, involving a two-year transition of responsibilities outside the U.S. and payments of up to $1.6 billion.
• AstraZeneca in a worldwide out-license agreement with PhaseBio Pharmaceuticals, Inc. for a reversal agent for ticagrelor.
• Gilead in a series of transactions with two multinational pharmaceutical companies concerning the development and commercialization of Atripla, a triple combination HIV therapy, including various corporate and contractual arrangements for supply and distribution in the United States, the EU, and the access countries.
• AstraZeneca in the outlicense to Impax Pharmaceuticals of U.S. commercial rights for three versions of the migraine drug Zomig.
• UCB in connection with a strategic partnership pursuant to which it granted rights to Wilex AG, a German biotechnology company, with respect to a preclinical oncology portfolio, comprising two small-molecule programs and three antibody programs, and retained rights to reacquire such programs following completion of initial clinical feasibility studies.
• AstraZeneca in a strategic collaboration with Map Pharmaceuticals to develop and commercialize a Phase 3 product for the treatment of asthma, which involved upfront fees, milestones and funding commitments in excess of $900 million and a co-promotion option.
• P&G (formerly Gillette) in a worldwide licensing arrangement involving the acquisition of rights to exploit the first light-based aesthetic device to receive a 510(k) over-the-counter clearance from FDA.
• Allergan in the acquisition of Naurex, a clinical stage biopharmaceutical company developing therapies for CNS disorders.
• Astellas in a strategic partnership with Ambit to jointly develop and commercialize FLT3 kinase inhibitors for oncology and non-oncology indications; upfront of $40 million and pre-commercial payments of up to $350 million.
• UCB in an innovative research alliance with Harvard University to collaborate on drug development programs, including a first project to generate antibodies against a range of diseases, including diabetes and metabolic disorders.
• A pharmaceutical company on a research collaboration and option arrangement to develop cell-based therapeutics using genetically engineered natural killer cells with chimeric antigen receptor expression.
• AstraZeneca in a collaboration with A*Star, Singapore’s Agency for Science, Technology and Research and the Experimental Therapeutics Centre and Exploit Technologies plc, directed to drugs to treat gram-negative bacterial infections.
• AstraZeneca in its collaboration with Abbott to develop a combination product containing fenofibrate and AstraZeneca’s statin Crestor® for cholesterol management.
• A multi-national pharmaceutical company in various transactions, including the divestiture of an epidermal delivery technology, and in the divestiture of certain patent families from its gene therapy portfolio.
• Medarex in a global strategic alliance with a Japanese pharmaceutical company, involving the cross license of multiple platform technologies consisting of transgenic and transchromosomic mouse technologies, and in connection with a number of other collaboration agreements with pharmaceutical partners to exploit antibody products.

Representative M&A Transactions

• Life sciences transactions support and advisor role on numerous M&A transactions, including for example in:
  • Merck’s $11.5 billion acquisition of Acceleron Pharma
  • Merck’s $1.05 billion acquisition of Peloton Therapeutics
  • BMS’s $14 billion acquisition of Karuna Therapeutics
  • BMS’s $4.1 billion acquisition of RayzeBio
  • Astellas’s $3 billion acquisition of Audentes